Skip Ribbon Commands
Skip to main content
Skip to main navigation Skip to main content
Sign In

Astellas UK’s suspension from membership of the ABPI extended

23/06/2017
Astellas UK was suspended from membership of the Association of the British Pharmaceutical Industry (ABPI) with effect from 24 June 2016.  This has been extended for a further 12 months.

​​​

The original suspension was in connection with a serious matter which came to light during the PMCPA consideration of two complaints and, as a consequence, Astellas UK and Astellas Europe were reported to the ABPI Board.

In addition, three cases arising from voluntary admissions made between October 2016 and February 2017, Case AUTH/2883/10/16 and Cases AUTH/2939/2/17 and AUTH/2940/2/17, were reported to the Code of Practice Appeal Board which reported them to the ABPI Board.

Both companies have been audited, re-audited and will be re-audited in October 2017.

Full details can be found in the case reports, Case AUTH/2780/7/15 and AUTH/2747/1/15​, Case AUTH/2883/10/16 and Cases AUTH/2939/2/17 and AUTH/2940/2/17.

The ABPI has issued a press release which can be found here​.